Lophora

Description: Lophora develops rapid-acting CNS drugs, starting with treatment-resistant depression, using a novel psilocybin-like ligand class. Advancing to human trials in 2023.

Country: Denmark

Based in: Copenhagen

Founded: 2018

Funding Stage: Seed

Tags: ['Biotechnology']

Categories

Add insights to your inbox

We’ll send you content you’ll want to read- and put to use.

Details about how we process your information are available in our Privacy Policy.